Dermatopathology and COVID-19

A special issue of Dermatopathology (ISSN 2296-3529).

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 29593

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Dermatology, University Hospital of Geneva, 1205 Geneva, Switzerland
2. Department of Clinical Pathology, University Hospital of Geneva, 1205 Geneva, Switzerland
Interests: molecular pathology of skin aging and dermatoporosis; clinicopathological correlation in inflammatory dermatoses; pathology of melanocytic lesions; molecular dermatopathology; dermatotoxicopathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

With the growing number of cases with skin manifestations related to COVID-19, we have decided to dedicate a Special Issue to this subject. This Special Issue aims to cover these cutaneous lesions, which may be quite diverse. The major clinical forms described were maculopapular eruptions, acral areas of erythema with vesicles or pustules (pseudochilblain), urticarial lesions, other vesicular eruptions, and livedo or necrosis. The histopathological features of these lesions also vary, corresponding to the diversity of clinical manifestations. These features underline the nature of epidermal and dermal vascular lesions—and in severe cases, microvascular injury and thrombosis—associated with COVID-19 and provide important clues to their pathological mechanisms.

Prof. Dr. Gürkan Kaya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Dermatopathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • skin lesions
  • COVID-19
  • SARS-CoV-2
  • histopathology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 93415 KiB  
Article
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
by Dennis Niebel, Joerg Wenzel, Dagmar Wilsmann-Theis, Jana Ziob, Jasmin Wilhelmi and Christine Braegelmann
Dermatopathology 2021, 8(4), 463-476; https://doi.org/10.3390/dermatopathology8040049 - 27 Sep 2021
Cited by 24 | Viewed by 5771
Abstract
(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of [...] Read more.
(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms. Full article
(This article belongs to the Special Issue Dermatopathology and COVID-19)
Show Figures

Figure 1

Review

Jump to: Research, Other

32 pages, 2487 KiB  
Review
The Impact of COVID-19 Pandemic on Dermatological Conditions: A Novel, Comprehensive Review
by Gehan A. Pendlebury, Peter Oro, William Haynes, Drew Merideth, Samantha Bartling and Michelle A. Bongiorno
Dermatopathology 2022, 9(3), 212-243; https://doi.org/10.3390/dermatopathology9030027 - 29 Jun 2022
Cited by 9 | Viewed by 10742
Abstract
Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019. Since the declaration as a pandemic on 11 March 2020, further dermatological conditions continue to be documented. We herein present a novel literature review [...] Read more.
Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019. Since the declaration as a pandemic on 11 March 2020, further dermatological conditions continue to be documented. We herein present a novel literature review of dermatological manifestations associated with the Coronavirus Disease 2019 (COVID-19) pandemic. To date, this literature review is the first broad-spectrum examination that analyzes a range of dermatological manifestations related to the COVID-19 pandemic: infection, vaccinations, personal protective equipment (PPE), and psychosocial factors. Methods: A detailed literature search was conducted using key terms for cutaneous manifestations associated with the scope of this review. The search retrieved 2199 articles. Results: The COVID-19 pandemic has triggered a significant range of dermatologic sequela. Etiologies of lesions continue to be investigated. Proposed mechanisms include inflammatory response to spike protein, vitamin D deficiency, ACE2 receptor activation, androgen levels, and increased psychological stress. One prominent mechanism describes viral spike protein invasion into the dermis by binding to the angiotensin-converting enzyme 2 (ACE-2) receptors in keratinocytes, with a secondary immunological response. Conclusions: Dermatologists play an integral role in the proper diagnosis and treatment of COVID-related lesions. Early treatment regimens and timely prophylaxis have been shown to safely reduce infection-related dermatological sequelae. Additional investigations and data collection can reduce disease burden and improve overall prognosis. Full article
(This article belongs to the Special Issue Dermatopathology and COVID-19)
Show Figures

Figure 1

Other

Jump to: Research, Review

7 pages, 3068 KiB  
Case Report
Pityriasis Lichenoides et Varioliformis Acuta as a Complication of COVID-19 Infection
by Henriette De La Garza, Elie Saliba, Monica Rosales Santillan, Candice Brem and Neelam A. Vashi
Dermatopathology 2022, 9(3), 244-250; https://doi.org/10.3390/dermatopathology9030028 - 5 Jul 2022
Cited by 2 | Viewed by 8520
Abstract
Pityriasis lichenoides is an acute and/or chronic skin disease associated with recurrent erythematous papules that self-resolve. While its etiology is unknown, preceding viral infection may play a role. We present an atypical case of a 40-year-old woman with pityriasis lichenoides et varioliformis acuta [...] Read more.
Pityriasis lichenoides is an acute and/or chronic skin disease associated with recurrent erythematous papules that self-resolve. While its etiology is unknown, preceding viral infection may play a role. We present an atypical case of a 40-year-old woman with pityriasis lichenoides et varioliformis acuta as a complication of a COVID-19 infection. Full article
(This article belongs to the Special Issue Dermatopathology and COVID-19)
Show Figures

Figure 1

4 pages, 810 KiB  
Case Report
Pseudo-Pemphigoid Gestationis Eruption Following SARS-CoV-2 Vaccination with mRNA Vaccine
by Caroline de Lorenzi, Gürkan Kaya and Laurence Toutous Trellu
Dermatopathology 2022, 9(3), 203-206; https://doi.org/10.3390/dermatopathology9030025 - 24 Jun 2022
Cited by 1 | Viewed by 3101
Abstract
Auto-immune reactions, including auto-immune bullous disease, have been reported following SARS-CoV-2 virus vaccination. Few cases of bullous pemphigoid are described, but there has been no case of pemphigoid gestationis. We report the first case here. Full article
(This article belongs to the Special Issue Dermatopathology and COVID-19)
Show Figures

Figure 1

Back to TopTop